Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.53 |
| ▸ | NPY4R | P50391 | 8/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.46 |
| ▸ | NPY1R | P25929 | 5/20 | 0.46 |
| ▸ | NPY2R | P49146 | 3/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.42 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30562699 | 1.00 | APLNR (0.53) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31148815 | 0.96 | NPY4R (0.49) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31632213 | 0.93 | NPY4R (0.47) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30436618 | 0.91 | APLNR (0.46) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL5955065 | 0.90 | NPY4R (0.57) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16508547 | 0.90 | NPY4R (0.49) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30740007 | 0.89 | APLNR (0.50) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31474897 | 0.89 | APLNR (0.50) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29942005 | 0.88 | SLC6A5 (0.51) | APLNRNOD1 | |
| SCHEMBL16508437 | 0.88 | NPY4R (0.46) | APLNRNPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446393-B2 | Non-viral gene delivery agent comprising lipopeptide (LP) compounds | MONASH UNIVERSITY (AU) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446393-B2 | Non-viral gene delivery agent comprising lipopeptide (LP) compounds | LNPEP, TLR9, LPXN | APLNR 22/4885NPY4R 2187/4885NPY5R 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.